Recursion Pharmaceuticals grew its share prices for a fourth straight day on Monday, adding 9.59 percent to close at $6.40 ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals RXRX faced a significant setback in May 2025 after announcing the discontinuation of three key drug candidates — REC-994, REC-2282, and REC-3964 — as part of its broader ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.68% at $6.43. This change lagged the S&P 500's 0.78% gain on the day. Elsewhere, the Dow gained 1.14%, while the tech-heavy ...

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Shares in biotech company Recursion Pharmaceuticals ( RXRX 3.35%) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline.

Recursion states that REC-1245 is the first program using the company’s end-to-end AI platform, spanning discovery, biology, chemistry, and the clinic.

Recursion, a leader in AI-based drug development, has met the hype-or-hope challenge head-on, by going public since June with plans to announce clinical data from at least seven pipeline ...